WOMEN'S ROGAINE FOAM 5% 5 % — DIN 02424703
MINOXIDIL : 5 % · JOHNSON & JOHNSON INC · AEROSOL, FOAM · wholesale supply in Canada
Health Canada status: MARKETED
What is WOMEN'S ROGAINE FOAM 5%?
WOMEN'S ROGAINE FOAM 5% 5 % contains MINOXIDIL : 5 %. It is listed in the Health Canada Drug Product Database under DIN 02424703, held by JOHNSON & JOHNSON INC, supplied as AEROSOL, FOAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 24-Dec-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is WOMEN'S ROGAINE FOAM 5% used for?
Treatment of androgenetic alopecia (male/female pattern hair loss) on the top of the scalp (vertex). Effectiveness on receding hairlines not demonstrated.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Minoxidil, Topical in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Minoxidil, Topical, across 16 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JOHNSON & JOHNSON INC | 3 | 3 | MEN'S ROGAINE, MEN'S ROGAINE FOAM 5%, WOMEN'S ROGAINE FOAM 5% | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 2 | 2 | MEN'S MINOXIDIL FOAM, WOMEN'S MINOXIDIL FOAM | Sourceable in Canada |
| VITA HEALTH PRODUCTS INC | 3 | 1 | HAIR REGROWTH FORMULA, HAIR REGROWTH TREATMENT, HAIRGRO | Sourceable in Canada |
| GLENMARK PHARMACEUTICALS CANADA INC. | 2 | 1 | MEN'S GLN-MINOXIDIL, WOMEN'S GLN-MINOXIDIL | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-GAIN LIQ 20MG/ML, HAIR REGROWTH TREATMENT | No marketed DIN |
| ALTIMED PHARMA INC. | 1 | 0 | MINOXIGAINE TOPICAL SOLUTION - 2% | No marketed DIN |
| GENPHARM ULC | 1 | 0 | GEN-MINOXIDIL LIQ 2% | No marketed DIN |
| JAMP PHARMA CORPORATION | 1 | 0 | JAMP MINOXIDIL SOLUTION | No marketed DIN |
| LABORATOIRE RIVA INC. | 1 | 0 | MINOX | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 % |
|---|---|
| Dosage form | AEROSOL, FOAM |
| Route | TOPICAL |
| Pack configuration (monograph) | Solution: 60 mL bottle with child-resistant dropper. Foam: 60 g aluminum pressurized container with child-resistant cap (packs of 1, 2, or 3 cans). |
| Storage | Not explicitly stated in the provided text (refer to section 11 in full monograph). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Minoxidil, Topical |
|---|---|
| ATC code | D11AX01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02424703 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2424703 |
| Brand name | WOMEN'S ROGAINE FOAM 5% |
| Generic / active ingredient | MINOXIDIL : 5 % |
| Market authorization holder | JOHNSON & JOHNSON INC |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| ATC code | D11AX01 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D11AX |
| Current status | MARKETED |
| Status date | 24-Dec-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Solution: 1 mL twice daily. Men's Foam: 1/2 capful twice daily. Women's Foam: 1/2 capful once daily. Apply to dry scalp. Wash hands after use. Do not exceed recommended daily dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Pregnant/breastfeeding women; history of hypersensitivity to minoxidil; treated/untreated hypertension; non-hereditary hair loss; scalp abnormalities (psoriasis, sunburn, broken/inflamed skin).
Warnings and precautions
For external use only. Avoid contact with eyes/mucous membranes. Stop use if chest pain, rapid heartbeat, faintness, dizziness, or sudden weight gain occurs. May change hair color/texture.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 16 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HAIR REGROWTH FORMULA | 20 MG | SOLUTION | VITA HEALTH PRODUCTS INC | MARKETED | 02356597 |
| MEN'S GLN-MINOXIDIL | 5 % | AEROSOL, FOAM | GLENMARK PHARMACEUTICALS CANADA INC. | MARKETED | 02553465 |
| MEN'S MINOXIDIL FOAM | 5 % | AEROSOL, FOAM | TARO PHARMACEUTICALS INC | MARKETED | 02551446 |
| MEN'S ROGAINE | 20 MG | SOLUTION | JOHNSON & JOHNSON INC | MARKETED | 00708925 |
| MEN'S ROGAINE FOAM 5% | 5 % | AEROSOL, FOAM | JOHNSON & JOHNSON INC | MARKETED | 02368684 |
| WOMEN'S MINOXIDIL FOAM | 5 % | AEROSOL, FOAM | TARO PHARMACEUTICALS INC | MARKETED | 02551659 |
| APO-GAIN LIQ 20MG/ML | 20 MG | SOLUTION | APOTEX INC | DORMANT | 00885754 |
| GEN-MINOXIDIL LIQ 2% | 2 % | LIQUID | GENPHARM ULC | CANCELLED POST MARKET | 02065800 |
| HAIR REGROWTH TREATMENT | 2 % | SOLUTION | VITA HEALTH PRODUCTS INC | CANCELLED POST MARKET | 02242377 |
| HAIR REGROWTH TREATMENT | 2 % | SOLUTION | APOTEX INC | APPROVED | 02460181 |
2 · Same class — other molecules in ATC D11AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pyrithione Zinc | 2 IN 1 ANTI-DANDRUFF SHAMPOO AND CONDITIONER · 2 IN 1 CONDITIONING DANDRUFF SHAMPOO · 2 IN 1 CONDITIONING DANDRUFF TREATMENT SHAMPOO · 2 IN 1 DANDRUFF RELIEF SHAMPOO & CONDITIONER · +343 more | 363 | 67 | Yes |
| Finasteride | AURO-FINASTERIDE 1MG · FINASTERIDE · JAMP FINASTERIDE TABLETS · MINT-FINASTERIDE · +5 more | 10 | 8 | Yes |
| Minoxidil, Topical | APO-GAIN LIQ 20MG/ML · GEN-MINOXIDIL LIQ 2% · HAIR REGROWTH FORMULA · HAIR REGROWTH TREATMENT · +11 more | 16 | 7 | Yes |
| Ivermectin | PMS-IVERMECTIN · ROSIVER | 2 | 2 | Yes |
| Hydroquinone | ACTIVE 4 · AFRICAN GOLD SKIN DISCOLORATION FADE CRM 2% · AMBI EXTRA SKIN DISCOLORATION FADE CREAM · BANISHING CREAM · +63 more | 67 | 1 | Yes |
| Brimonidine | ONRELTEA | 1 | 1 | Yes |
| Eflornithine | VANIQA | 1 | 1 | Yes |
| Deoxycholic Acid | BELKYRA | 1 | 1 | Yes |
| Other Dermatologicals | DERMAGRAN II OINTMENT-ONT TOP 0.25% · SHUR-CLENS SOLN 20% · WITCH HAZEL | 3 | 0 | Not in Canada |
| Monobenzone | BENOQUIN CRM 20% | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D11A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D11AH | Abrocitinib · Alitretinoin · Crisaborole · Delgocitinib · Dupilumab · +5 more | 25 | 19 |
| D11AF | Wart And Anti-Corn Preparations | 33 | 1 |
| D11AA | Antihidrotics | 397 | 0 |
| D11AC | Cetrimide · Medicated Shampoos · Others · Povidone-Iodine · Selenium Compounds · +1 more | 27 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.